Journal profile · Cardiac & Cardiovascular Systems

Cardiovascular Therapeutics

ISSN 1755-5914 · eISSN 1755-5922 · John Wiley & Sons, Inc. · USA · Quarterly · Founded 2008

Cardiovascular Therapeutics: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.7; fully open access; APC about USD 2,380; median 193 days to acceptance (102 articles, last 24 months); community-reported acceptance: about 95%; 66 articles in 2025; indexed in SCIE and Scopus.

Impact factor2.7Latest value listed by LetPub
CAS zoneZone 3 · Medicine2025 upgraded edition, major category · 2026 Xinrui edition Zone 3 · Medicine
Review time193 daysMedian, submission to acceptance · 102 articles, last 24 months · Crossref
APCUSD 2,380Fully open access
Acceptanceabout 95%Community average
Articles per year662025 · OpenAlex count

Scope

Aims, scope and focus

Cardiovascular Therapeutics is published by John Wiley & Sons, Inc. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Atrial Fibrillation Management and Outcomes, Lipoproteins and Cardiovascular Health and Heart Failure Treatment and Management, together about 24% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)

Cardiovascular Therapeutics is an open access journal publishing original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of novel cardiovascular therapies.

From the journal's Aims & Scope

Research area (LetPub): Cardiac & Cardiovascular Systems

Editor-in-chief Baohui XuPublisher website

Main research topics OpenAlex counts of recent articles; shares are approximate

  1. Atrial Fibrillation Management and OutcomesMedicine9.8%
  2. Lipoproteins and Cardiovascular HealthMedicine7.4%
  3. Heart Failure Treatment and ManagementMedicine6.9%
  4. Cardiovascular Function and Risk FactorsMedicine6.9%
  5. Antiplatelet Therapy and Cardiovascular DiseasesMedicine6.8%
  6. Cardiac Fibrosis and RemodelingMedicine5.7%
  7. Coronary Interventions and DiagnosticsMedicine5.5%
  8. Cardiac electrophysiology and arrhythmiasMedicine5.5%

Rankings & indexing

CAS ranking and database indexing

CAS Journal Ranking

CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
LevelCategoryZone
MajorMedicineZone 3
MinorCardiac & Cardiovascular SystemsZone 3
MinorPharmacology & PharmacyZone 3

Top journal: noReview journal: no

CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
LevelCategoryZone
MajorMedicineZone 3
MinorCardiac & Cardiovascular SystemsZone 3
MinorPharmacology & PharmacyZone 3

Top journal: noReview journal: not marked

CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
LevelCategoryZone
MajorMedicineZone 4
MinorPharmacology & PharmacyZone 3
MinorCardiac & Cardiovascular SystemsZone 4

Top journal: noReview journal: no

Database indexing

SCIEScopusDOAJLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Metrics

Impact metrics and publication volume

Impact

Impact factor
2.7LetPub ·
Impact factor (publisher)
2.8Publisher website ·
CiteScore 2026-06
6.1LetPub ·
CiteScore (publisher)
6.1Publisher website ·
SJR 2026-06
0.86LetPub ·
SNIP 2026-06
0.98LetPub ·
h-index
39LetPub ·
h-index
69OpenAlex ·
i10-index
608OpenAlex ·
2-year mean citedness
2.37OpenAlex ·
Self-citation rate
3.6%LetPub ·
Share of gold OA articles
100%LetPub ·

Volume

Articles per year
64LetPub ·

Articles by year OpenAlex count · 1,190 in total · the current year is incomplete

YearArticlesOpen accessCitations
2026818125
20256666141
20243636268
20233434282
202268681,199
20213737645

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Review & acceptance

Review time and acceptance

Review time from article dates manuscript dates registered with Crossref · to

193 daysMedian, submission to acceptance · P25–P75 149 days – 237 days

Acceptance to online
median 30 days (102 articles)
Submission to online
median 223 days
Sample
102 articles with submission and acceptance dates (142 in the window); the latest was accepted on

Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".

Other sources

Average review time (community reports)
about 6 monthsLetPub ·
Average acceptance (community reports)
95%LetPub ·
Acceptance rate (publisher)
17%Publisher website ·
Submission to first decision
61 daysPublisher website ·
Submission to publication (journal-reported)
about 19 weeksDOAJ ·
Peer review
Single anonymous peer reviewDOAJ

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

Fees & open access

APC and open-access policy

Fully open accessDOAJ

Every article is open access; authors usually pay an article processing charge (APC).

SourceAPCFee waiverLicenseObserved
DOAJUSD 2,380 / GBP 1,590 / EUR 1,880YesCC BY
OpenAlexUSD 2,160 / EUR 1,880 / GBP 1,590——
Publisher websiteYes, amount not published——

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Submission

Article types and submission policies (journal website)

What to prepare3 items from the author guidelines
Reference style
Numbered, in order of citation
First submission
Free format: the journal's layout is not required
Cover letter
Optional
Publisher website · model-extracted, each line checked against the text
Article types accepted5
  1. editorialCardiovascular Therapeutics publishes the following types of submissions: Original Research Review Article Editorial Letter to the EditorLength not stated
  2. letter to the editorCardiovascular Therapeutics publishes the following types of submissions: Original Research Review Article Editorial Letter to the EditorLength not stated
  3. original researchCardiovascular Therapeutics publishes the following types of submissions: Original Research Review Article Editorial Letter to the EditorLength not stated
  4. research articleResearch Article Open access Zhenwu Decoction Attenuates Water‐Retention–Related PhenotypesLength not stated
  5. review articleCardiovascular Therapeutics publishes the following types of submissions: Original Research Review Article Editorial Letter to the EditorLength not stated
Publisher website
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Preprints, Self-archiving, Trial registration / reporting guidelines
AI use Disclosing the use of artificial intelligence (AI)

If you or your co-authors have used Artificial Intelligence Generated Content (AIGC) tools such as ChatGPT and others based on large language models (LLMs) to develop any portion of a manuscript, their use must be described transparently and in detail in the Methods section. Find more details on Wiley’s AI guidelines for researchers and Wiley’s AI policy in full in the Best Practices Guidelines on…

Source ↗Publisher website ·
Authorship Authorship

All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. You can review the Authorship section of Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics for Wiley’s definition of authorship.

Source ↗Publisher website ·
Conflicts of interest Conflicts of Interest (COIs)

A common reason for third-party complaints of published articles is an allegation that author(s) have not fully disclosed perceived conflicts of interest (COIs). Such complaints may lead to ethics investigations by the journal and publisher. Therefore, when submitting your manuscript, you should disclose any potential conflicts of interests (also referred to as “competing interests”) that might ap…

Source ↗Publisher website ·
Data availability Data Sharing

This journal encourages data sharing. You can learn more about data sharing in Wiley’s Data Sharing Policies resource.

Source ↗Publisher website ·
Publication ethics COPE

This journal adheres to the ethical standards set by the Committee on Publication Ethics (COPE) to uphold integrity in scholarly research and publishing. While COPE previously organized its guidance around "core practices," these have since been replaced with a topic-based structure to better reflect the evolving needs of the research community. You can learn more about this transition and explore…

Source ↗Publisher website ·
License & copyright Copyright and licensing

This is an open access journal. Authors of accepted papers pay an Article Publication Charge (APC) and their papers are published under a Creative Commons (CC) license. For more information on this journal’s APCs and licensing policy, please visit this journal’s Open Access page. Note: Some funders require authors to use a particular type of CC license. Please check directly with your funder to de…

Source ↗Publisher website ·
Open access Open access

Open access journal Model summary

This is an open access journal. Submissions will be subject to an Article Publication Charge (APC) if accepted and published in the journal. Please read more about APCs and whether you may be eligible for waivers or discounts through your institution, your funder, or a country waiver at Wiley Author Services.

Source ↗Publisher website ·
Peer review Peer Review Model

Single-anonymized peer review model Model summary

We follow a single-anonymized peer review model, for applicable article types. Except where otherwise stated, manuscripts are peer reviewed by at least one anonymous reviewer and an Associate or Assistant Editor. Papers authored by Editors or Editorial Board members of the journal will be sent to Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer…

Source ↗Publisher website ·
Preprints Preprint Policy

The journal accepts articles previously published on preprint servers and does not consider this to compromise the novelty of the results. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered. The preprint should be cited. You will be asked to update any pre-publication versions with a link to the final published ar…

Source ↗Publisher website ·
Self-archiving Self-Archiving definitions and policies

This journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. You can learn more by reading Wiley’s self-archiving policy.

Source ↗Publisher website ·
Trial registration / reporting guidelines Reporting guidelines

Authors are strongly encouraged to use appropriate reporting guidelines when preparing and submitting manuscripts, to maximize transparency and reproducibility. Our editors and reviewers are also encouraged to use them in the review process. Completed checklists should be provided in the supplementary files on submission. We particularly encourage the use of: Wiley Biological and Biomedical Scienc…

Source ↗Publisher website ·

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Profile

Publication details and official links

Publisher
John Wiley & Sons, Inc.
Country or region
USA
Language
English
Frequency
Quarterly
Founded
2008
ISSN
1755-5914
Electronic ISSN
1755-5922
Official links

FAQ

Frequently asked questions about Cardiovascular Therapeutics

What CAS zone is Cardiovascular Therapeutics in?

In the 2025 upgraded edition of the CAS Journal Ranking, Cardiovascular Therapeutics is in Zone 3 of Medicine, and in Zone 3 of the minor category Cardiac & Cardiovascular Systems / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.

What is the impact factor of Cardiovascular Therapeutics?

The latest impact factor listed by LetPub is 2.7; CiteScore 6.1, h-index 69.

How long does peer review take at Cardiovascular Therapeutics?

Based on the dates recorded on 102 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 193 days (interquartile range 149–237 days); authors report an average review time of about 6 months; the community-reported acceptance is “about 95%”; the journal's website gives an acceptance rate of 17%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.

What are the manuscript requirements of Cardiovascular Therapeutics?

According to the journal's author guidelines: Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Cover letter: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.

Which databases index Cardiovascular Therapeutics?

According to LetPub and DOAJ records, Cardiovascular Therapeutics is indexed in SCIE, Scopus and DOAJ.

Is Cardiovascular Therapeutics open access, and what is the APC?

Cardiovascular Therapeutics is a fully open-access journal. APC about USD 2,380.

Sources and updates

The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .